Overview

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
Otsuka America Pharmaceutical
Treatments:
Aripiprazole
Criteria
Inclusion Criteria:

- Primary diagnosis of idiopathic Parkinson's disease.

- Psychosis related to Parkinson's disease.

Exclusion Criteria:

- Psychosis present prior to diagnosis of Parkinson's disease.